At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 24 enrolled
Drug / intervention
DFN-11drug
Likely dose
DFN-11 3 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Double-Blind, Crossover, Comparator Pilot Study of DFN-11 Injection (Strength A vs. Strength B) for Rapidly Escalating Migraine
In Brief
A Phase 2 clinical trial evaluating DFN-11 for Rapidly Escalating Migraine. Completed, enrolled 24 participants across 1 site.
Detailed Summary
Pilot study to compare the efficacy and safety of two strengths of injections of subcutaneous DFN-11 in subjects with rapidly escalating migraine headaches.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRapidly Escalating Migraine
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartSep 2015
First PostedOct 2015
Primary CompletionApr 2016
Study CompletionMay 2016
TodayJul 2026
First PostedOct 8, 2015
Enrollment StartSep 1, 2015
Primary CompletionApr 1, 2016
Study CompletionMay 1, 2016
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 10.7 years ago
Interventions
DFN-11drug
Sumatriptan 3 mg versus 6 mg